Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10258-10263

  Tort, Frederic ^a   Bartkova, Jirina ^a   Sehested, Maxwell ^b   Oørntoft, Torben ^c   Lukas, Jiri ^a   Bartek, Jiri ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN E; PROTEIN P16;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL CULTURE; CELL CYCLE; COLORECTAL ADENOMA; CONTROLLED STUDY; DEREGULATION; DNA DAMAGE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINOBLASTOMA;

CELL LINE, TUMOR; CYCLIN D1; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA DAMAGE; E2F1 TRANSCRIPTION FACTOR; GENES, P53; HUMANS; NEOPLASMS; RETINOBLASTOMA PROTEIN;

EID: 33751293168     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2178     Document Type: Article

References (20)

1. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996;8:805-14.
2. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004;432:316-23.
3. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
4. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
5. Bartkova J, Horejsi Z, Koed K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005;434:864-70.
6. Gorgoulis VG, Vassiliou LV, Karakaidos P, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005;434:907-13.
7. 1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 1995;15:2600-11.
8. Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J. Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 1994;9:707-18.
9. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 2002;12:l817-27.
10. 1 and E with an inducible system. Mol Cell Biol 1994;14:1669-79.
11. Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001;2:731-7.
12. Ekholm-Reed S, Mendez J, Tedesco D, Zettenberg A, Stillman B, Reed SI. Deregulation of cyclin E in human cells interferes with replication complex assembly. J Cell Biol 2004;165:789-800.
13. Pickering MT, Kowalik TF. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 2006;25:746-55.
14. DiTullio RA, Jr., Mochan TA, Venere M, et al. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002;4:998-1002.
15. Norberg T, Haar S, Karf G, Nordgren H, Holmberg L, Bergh J. Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort. Cancer Res 2001;61:8317-21.
16. Alsner J, Yilmaz M, Guldberg P, Hansen LL, Overgaard J. Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients. Clin Cancer Res 2000;6:3923-31.
17. Elsaleh H, Powell B, McCaul K, et al. p53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage HI colorectal carcinoma. Clin Cancer Res 2001;7:1343-9.
18. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
19. Loden M, Stighall M, Nielsen NH, et al. The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 2002;21:4680-90.
20. Lindahl T, Landberg G, Ahlgren J, et al. Over-expression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer. Carcinogenesis 2004;25:375-80.